Skip to main content
. 2017 Feb 28;112(5):763–774. doi: 10.1038/ajg.2017.41

Figure 3.

Figure 3

Mean average weekly number of CSBMs over time (intention to treat analysis set). *P<0.050, tenapanor 50 mg b.i.d. vs. placebo. P<0.050, tenapanor 20 mg b.i.d. and tenapanor 50 mg b.i.d. vs. placebo. P values were based on an analysis of covariance model with treatment and pooled investigator site as factors and baseline value as a covariate. b.i.d., twice daily; CSBM, complete spontaneous bowel movement.